Anticipate FDA feedback on clinical hold for AMR in Q2, 2025. Target IND submission for Aplastic Anemia in Q2, 2025. Report the interim data from the ongoing ITP phase 1 study in mid-2025. Anticipate finalizing the equity transfer agreement regarding Precision Autoimmune Therapeutics in Q2 2025. Upon completion of this transaction, CASI will have the sole global ownership of all indications in CID-103.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CASI:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue